ISSN:
1569-8041
Keywords:
dosing
;
inhibitor
;
matrix metalloproteinase
;
pharmacokinetics
;
solid tumours
;
toxicity
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:This phase I study was performed to evaluatethe safety, tolerability, and efficacy of the oral matrixmetalloproteinase inhibitor BAY 12-9566 in patients with advanced solidtumours, and to identify the maximum tolerated dose and dose for use insubsequent studies. Patients and methods:BAY 12-9566 was administered to 29 patientsat doses ranging from 100 mg o.d. to 1600 mg (given either 400 mg q.i.d. or800 mg b.i.d.). Blood samples for pharmacokinetic analyses were drawn on days1–5, day 15 and days 29 and 30. Patients were continued on daily oraltreatment of BAY 12-9566 until a dose limiting toxicity or tumour progressionoccurred. Results:A maximum tolerated dose was not defined because plasmalevels of BAY 12-9566 could not be sufficiently increased, even withescalating doses of drug. Pharmacokinetic analysis suggested that absorptionwas saturable at higher doses. The predominant toxicities related to drug wereasymptomatic reversible effects on platelets and transaminases and mildanemia. There were no significant musculoskeletal toxicities. No objectiveresponses were seen at the doses tested, but stable disease was observed insome patients based on tumour measurements. Conclusions:The recommended dose of BAY 12-9566 for furtherstudies is 800 mg b.i.d. as this dose provides maximal plasma levels that canbe achieved with a convenient dosing schedule for a chronically administeredoral agent
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008347630465
Permalink
